PEGylated liposomes containing PI3Kγ inhibitor Eganelisib (IPI-549). Eganelisib (IPI-549) is a potent and selective PI3Kγ inhibitor (IC50 16 nM) which is reported to exhibit more than 100-fold selectivity over other lipid and protein kinases and potentiate immunotherapy with immune checkpoint inhibitors in mice. IPI-549 is insoluble in aqueous media. This product is a pre-formulated liposomal version of IPI-549 which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.